Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Hufton, GB

Simon Hufton, Lancashire GB

Patent application numberDescriptionPublished
20100061993Antibodies - A human antibody fragment, which antibody or fragment: 03-11-2010

Simon E. Hufton, Lancs GB

Patent application numberDescriptionPublished
20100196361Method of inhibition of vascular development using an antibody - Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity and angiogenesis. The agents can be used to treat angiogenesis-associated disorders.08-05-2010
20110059105TIE COMPLEX BINDING PROTEINS - Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity.03-10-2011

Patent applications by Simon E. Hufton, Lancs GB

Simon E. Hufton, Clitheroe Lanes GB

Patent application numberDescriptionPublished
20110009280MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF - A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set). The use of such matched vector sets provides flexibility and versatility in the generation of eukaryotic display libraries, for example the ability to generate and to display multi-chain polypeptides by combining and recombining vectors that express variegations of the individual chains of a multi-chain polypeptide. Entire repertoires of novel chain combinations can be devised using such vector sets.01-13-2011

Simon E. Hufton, Clitheroe GB

Patent application numberDescriptionPublished
20080254021TIE1-BINDING LIGANDS - Tie1 is a receptor tyrosine kinase protein that includes a transmembrane domain. Tie1 is present on endothelial cells. This disclosure described antibodies that bind to Tie1, including ones that inhibit endothelial cell activity.10-16-2008

Patent applications by Simon E. Hufton, Clitheroe GB

Simon Evan Hufton, Hitchin GB

Patent application numberDescriptionPublished
20100113304COMPATIBLE DISPLAY VECTOR SYSTEMS - The present invention provides a polynucleotide vector system used during polypeptide display that can be used to facilitate transfer of pools of polynucleotides encoding antigen binding proteins of interest. The present invention also provides methods that allow seamless conversion of pools of polynucleotides encoding antigen binding proteins using a restriction enzyme digestion and ligation strategy.05-06-2010
20100120634COMPATIBLE DISPLAY VECTOR SYSTEMS - The present invention provides a polynucleotide vector system used during polypeptide display that can be used to facilitate transfer of pools of polynucleotides encoding antigen binding proteins of interest. The present invention also provides methods that allow seamless conversion of pools of polynucleotides encoding antigen binding proteins using a restriction enzyme digestion and ligation strategy.05-13-2010
20100124764SINGLE CHAIN ANTIBODY LIBRARY DESIGN - The invention provides polynucleotide vectors and linkers and methods for designing and making single chain variable fragment (“ScFv”) libraries. The invention also provides polynucleotide vectors and linkers and methods for reformatting the ScFv library into Fab and IgG formats for high throughput production and screening.05-20-2010
20100143349HUMANIZED ANTI-RAGE ANTIBODY - Compositions comprising antigen binding polypeptides that bind specifically to Receptor For Advanced Glycation End-product (RAGE) and comprises: one or more complementarity determining regions (CDRs) with improved binding efficiency over a parental monoclonal antibody to RAGE are described. Antibodies containing the CDR's and methods of treating a RAGE-related disease or disorder comprising administering to the subject a therapeutically effective amount of the compositions of the invention are also provided.06-10-2010